Is blood pTau a reliable indicator of the CSF status? A narrative review

Antonioni, Annibale; Raho, Emanuela Maria; Di Lorenzo, Francesco

doi:10.1007/s10072-023-07258-x

Cited by 3 publications

(2 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, increasing efforts have been made to identify biomarkers in more accessible biological matrices, including urine, saliva, and blood [ 51 , 52 ]. The SIMOA platform is a novel method to study biomarkers of neurodegeneration in plasma, which makes the biomarker search much more feasible than a lumbar puncture [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

SIMOA Diagnostics on Alzheimer’s Disease and Frontotemporal Dementia

Chatziefstathiou,

Canaslan,

Kanata

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Background: Accurate diagnosis of Alzheimer’s disease (AD) and frontotemporal dementia (FTD) represents a health issue due to the absence of disease traits. We assessed the performance of a SIMOA panel in cerebrospinal fluid (CSF) from 43 AD and 33 FTD patients with 60 matching Control subjects in combination with demographic–clinical characteristics. Methods: 136 subjects (AD: n = 43, FTD: n = 33, Controls: n = 60) participated. Single-molecule array (SIMOA), glial fibrillary acidic protein (GFAP), neurofilament light (NfL), TAU, and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in CSF were analyzed with a multiplex neuro 4plex kit. Receiver operating characteristic (ROC) curve analysis compared area under the curve (AUC), while the principal of the sparse partial least squares discriminant analysis (sPLS-DA) was used with the intent to strengthen the identification of confident disease clusters. Results: CSF exhibited increased levels of all SIMOA biomarkers in AD compared to Controls (AUCs: 0.71, 0.86, 0.92, and 0.94, respectively). Similar patterns were observed in FTD with NfL, TAU, and UCH-L1 (AUCs: 0.85, 0.72, and 0.91). sPLS-DA revealed two components explaining 19% and 9% of dataset variation. Conclusions: CSF data provide high diagnostic accuracy among AD, FTD, and Control discrimination. Subgroups of demographic–clinical characteristics and biomarker concentration highlighted the potential of combining different kinds of data for successful and more efficient cohort clustering.

show abstract

Section: Discussionmentioning

confidence: 99%

SIMOA Diagnostics on Alzheimer’s Disease and Frontotemporal Dementia

Chatziefstathiou,

Canaslan,

Kanata

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…7,28 Several studies have shown that long-term brain changes and pathological biomarker accumulation (eg, amyloid and tau proteins) are associated with a prior history of moderate-to-severe TBI and have also validated that individuals with moderate-to-severe injuries develop a higher risk of dementia. [29][30][31][32] Many processes following TBI may cause circuit changes that result in subsequent epilepsy, especially inflammation, oxidative stress, and the later phases of neurodegeneration and regeneration. 15 Factors related to postinjury damage and age-related brain changes in cognitive decline and dementia.…”

Section: Introductionmentioning

confidence: 99%

Increasing Risk of Dementia Among Patients with Subsequent Epilepsy Within 2 Years Post-Traumatic Brain Injury: A Population‐Based Case-Control Study

Chu,

Liao,

Wei

2024

JMDH

View full text Add to dashboard Cite

Background Although the association between neurodegenerative diseases, such as dementia, and traumatic brain injury (TBI) has long been known, the association between dementia and TBI with epilepsy has been controversial. Aim This data-driven population-based study is designed to investigate the association between dementia and epilepsy after TBI within a 2-year period. Methods This case-control cohort study was conducted using the Longitudinal Health Insurance Database 2000 (LHID2000). We included 784 individuals ambulatory or hospitalized for TBI with epilepsy from 2001 to 2011, compared with 2992 patients with TBI without epilepsy who were matched for characteristics including sex, age, and healthcare resource use index date. Every participant was followed up for 5 years to ascertain any dementia development. Data were stratified and analyzed using the Cox proportional hazards regression. Results Through the 5-year follow-up period, 39 patients (5.21%) with TBI with epilepsy and 55 (1.53%) with TBI without epilepsy developed dementia. TBI with epilepsy was independently associated with a >3.03 times risk of dementia after correcting for age, sex, and comorbidities. Conclusion These findings suggest an increased risk of dementia in patients with TBI with epilepsy. Our research recommends that individuals with TBI and epilepsy be monitored more intensively.

show abstract

The Bayesian approach for real‐world implementation of plasma p‐tau217 in tertiary care memory clinics in Thailand

Thanapornsangsuth,

Booncharoen,

Khieukhajee

et al. 2024

Alzheimer's & Dementia

View full text Add to dashboard Cite

INTRODUCTIONPlasma phosphorylated tau (p‐tau)217 is a promising biomarker for Alzheimer's disease (AD) diagnosis, but its clinical implementation remains challenging. We propose a strategy based on Bayes’ theorem and test it in real‐life memory clinics.METHODSMemory clinic patients were evaluated by neurocognitive specialists for prespecified diagnosis and subsequently underwent blood collection for p‐tau217, cerebrospinal fluid, or amyloid positron emission tomography. Using cross‐validation, the Bayesian approach (pretest probability × individualized likelihood ratio) was compared to other models for AD diagnosis.RESULTSThe Bayesian strategy demonstrated an area under the receiver operating characteristic curve (AUC) of 0.98 (95% confidence interval [CI]: 0.96–1.0), significantly outperforming multivariable logistic regression (p‐tau217, age, apolipoprotein E; AUC 0.95, p = 0.024) and p‐tau217 alone (AUC = 0.94, p = 0.007). When applying the two‐threshold approach, the Bayesian strategy yielded an accuracy of 0.94 (95% CI: 0.88–1.0) without requiring confirmatory tests in 62.9% of the iterations.DISCUSSIONThe Bayesian strategy offers an effective and flexible approach to address the limitations of plasma p‐tau217 in clinical practice.Highlights Incorporating pretest probability into the interpretation of plasma phosphorylated tau (p‐tau)217 improves the diagnostic performance significantly. The strategy could obviate the need for confirmatory testing in most of the patients. Plasma p‐tau217 proves useful as a biomarker for Alzheimer's disease in low‐ and middle‐income country such as Thailand.

show abstract

Is blood pTau a reliable indicator of the CSF status? A narrative review

Cited by 3 publications

References 100 publications

SIMOA Diagnostics on Alzheimer’s Disease and Frontotemporal Dementia

SIMOA Diagnostics on Alzheimer’s Disease and Frontotemporal Dementia

Increasing Risk of Dementia Among Patients with Subsequent Epilepsy Within 2 Years Post-Traumatic Brain Injury: A Population‐Based Case-Control Study

The Bayesian approach for real‐world implementation of plasma p‐tau217 in tertiary care memory clinics in Thailand

Contact Info

Product

Resources

About